Abstract Ischemic preconditioning is an innate neuroprotective mechanism in which a sub-injurious ischemic exposure increases the brain's ability to withstand a subsequent, normally injurious ischemic insult. Part of ischemic preconditioning neuroprotection stems from an epigenetic reprogramming of the brain to a phenotype of ischemic tolerance, which results in a gene expression profile different from that observed in the non-injured and ischemia-injured brains. Such neuroprotective reprograming, activated by ischemic preconditioning, requires specific changes in DNA accessibility coordinated with activation of transcriptional activator and repressor proteins, which allows for expression of specific neuroprotective proteins despite a general repression of gene expression. In this review we examine the effects of injurious ischemia and ischemic preconditioning on the regulation of DNA methylation, histone post-translational modifications, and non-coding RNA expression. There is increasing interest in the role of epigenetics in disease pathobiology, and whether and how pharmacological manipulation of epigenetic processes may allow for ischemic neuroprotection. Therefore, a better understanding of the epigenomic determinants underlying the modulation of gene expression that lead to ischemic tolerance or cell death offers the promise of novel neuroprotective therapies that target global reprograming of genomic activity versus individual cellular signaling pathways.
Introduction
Cerebral ischemia results from the prolonged interruption of blood flow to the brain as a result of a stroke or cardiac arrest. Cerebral ischemia initiates a complex cascade of events leading to cell death both in the ischemic core and in the surrounding less severe ischemic tissue, where cell death continues for days and weeks following reperfusion. Most research aimed at preventing ischemia-mediated injury has focused primarily upon identifying the signaling pathways activated by ischemia/reperfusion and the pharmacological targeting of these pathways. However, this targeted approach has met with little success in the clinic [1] .
The lack of therapeutic success in the clinic against stroke and cardiac arrest has led many researchers to study intrinsic mechanisms of neuroprotection. One such approach is known as ischemic preconditioning (IPC). IPC can be elicited by a brief non-injurious interruption of blood flow, which initiates a neuroprotective response that protects the brain against a subsequent injurious ischemic exposure. Several IPC models have been used in preclinical studies to induce a non-injurious ischemic stress-including transient intraluminal suture induced occlusion of the middle cerebral artery (MCAO), a model of focal ischemia; cardiac arrest, and bilateral carotid artery cross-clamping with hypertension, models of global ischemia and oxygen and glucose deprivation (OGD), an in vitro model of ischemia.
Numerous research groups have identified signaling pathways activated by IPC that lead to neuroprotection (reviewed in [2] and [3] ) mediated partly through altered gene expression [4, 5] . Recent microarray analyses have revealed that the gene expression profiles of IPC, injurious ischemia, and IPC+ injurious ischemia are very different [6] [7] [8] [9] . For example, Stenzel-Poore et al. [9] compared gene expression of the ipsilateral cortex to the non-ischemic contralateral cortex 24 h following MCAO-induced preconditioning (15-min occlusion), injurious ischemia (60-min occlusion), or IPC followed 72 h later by injurious ischemia (ischemic tolerant). The genes regulated in each of these three conditions (IPC, injurious ischemia, and ischemic tolerant) were very different, with very little overlap among the three conditions. IPC induced expression of genes related to metabolic function and the cell cycle, whereas injurious ischemia upregulated genes involved in immune response and host defenses [9, 10] . In contrast to the major induction of gene expression observed in IPC and injurious ischemia, ischemia tolerance induced a distinct downregulation (77 %) of the differentially expressed genes [9, 10] . These suppressed genes encoded ion channels, transporters, and metabolic pathways, suggesting lowered cellular activity. These findings led to the notion that the brain's response to injurious ischemia is reprogramed by preconditioning from one that leads to cell death to one that produces a neuroprotective phenotype [9, 10] . Mechanistically, the prevailing view is that epigenetic remodeling underlies the reprogramming of genome activity involved in acquisition and maintenance of the neuroprotective phenotype. These epigenetic changes have only recently begun to be investigated in the preconditioned brain.
Epigenetics
Epigenetics is concerned with mitotically heritable changes in transcriptional potential. Mechanisms that underlie epigenetic regulation, through determination of the accessibility of DNA to the transcriptional machinery, include direct modification of DNA by methylation and a variety of chemical modifications of the proteins regulating chromatin structure, including histones and many nonhistone proteins. Noncoding RNAs (ncRNAs) mediate an additional mode of epigenetic regulation by influencing gene expression at multiple levels, including modulation of chromatin structure, RNA splicing, and mRNA stability and translatability.
These mechanisms ultimately regulate gene transcription, replication, and repair. Therefore, epigenetic changes allow cells to adapt and respond to changes in their internal and external environment [11] .
The current hypothesis states that the regulation of chromatin modifications by epigenetic factors during both normal and ischemic conditions directly influences the accessibility of the DNA to proteins that regulate gene expression, and lead to a cell death or survival phenotype [12] . Research from different groups has shown that IPC and injurious ischemia leading to epigenetic changes participate in cerebral protection or damage, respectively [6] [7] [8] [9] . Below we provide a summary describing epigenetic changes in DNA methylation, histone post-translational modifications, and non-coding RNA expression following IPC and injurious ischemia, which may play important roles in the genetic reprogramming of the cell to a phenotype of ischemic tolerance or intolerance.
DNA Methylation
DNA methylation of cytosine residues in gene promoter regions is an important and well-characterized epigenetic mechanism for regulation of gene expression (Fig. 1) . In general, DNA methylation at promoter regions represses gene expression whereas DNA hypomethylation is associated with gene transcription. The level of DNA methylation is regulated by the balance of the activities of DNA methyltransferases, which transfer a methyl group from S-adenosylmethionine to cytosine residues, and DNA demethylases, which remove methyl groups from the DNA. De novo methylation of DNA is mediated by DNA methyltransferase (DNMT)3a and 3b, whereas DNMT1 maintains the DNA methylation [13, 14] .
Cerebral ischemia affects the extent of DNA methylation [15, 16] . In a mouse model of focal cerebral ischemia, Endres et al. [16] observed that cerebral ischemia/reperfusion led to increased DNA methylation in brain tissues. The functional effect of this increased methylation on cell survival was demonstrated in DNA methyltransferase knockout mice, where reduced DNA methylation and lower cerebral ischemic damage were observed following 30 min of MCAO. They also demonstrated that inhibiting DNA methyltransferase using 5-aza-2'-deoxycytidine was neuroprotective against cerebral ischemic damage and was associated with reduced levels of DNA methylation. This study concluded that cerebral ischemiainduced DNA hypermethylation plays a key role in pathways leading to cerebral ischemic injury [16] . However, complete inhibition of DNA methylation is not advantageous as, in a follow-up study, the same group demonstrated that lower levels of DNMT1, but not complete absence of DNMT1, protected neurons from ischemic brain injury [17] , suggesting complex mechanisms of methylation-mediated damage/neuroprotection. In a different study, Hu et al. [18] demonstrated that OGDinduced suppression of thrombospondin-1 (TSP-1) (a potent angiostatic factor) was dependent upon DNA methylation of the TSP-1 promoter region. OGD was observed to increase methylation levels, which coincided with decreased TSP-1 mRNA and protein expression. Reperfusion following OGD resulted in decreased methylation, and increased TSP-1 mRNA and protein expression. They hypothesized that OGD leads to lower TSP-1 expression via increased methylation of the promoter region of TSP-1, which may, ultimately, increase angiogenesis [18, 19] .
A recent study has also demonstrated that genetic alterations in the DNA methylation pathway increase an individual's risk of stroke [15, 20] . Casas et al. [20] performed a meta-analysis of epidemiological studies and found that methylene-tetrahydrofolate reductase (an enzyme involved in the formation of cellular reservoirs of methyl groups) deficiency increases an individual's risk of stroke [15] . However, the effect of methylene-tetrahydrofolate reductase deficiency on ischemic damage, following a stroke, is not known.
These studies suggest that DNA hypermethylation plays an important and complex role in cerebral ischemia-induced damage, which could be reduced by DNMT inhibition ( Table 1 ). The effect of IPC on DNA methylation and the contribution of DNA methylation to IPC-mediated ischemic tolerance are currently undefined.
Histone Modifications
The compaction of DNA within the nucleus is achieved by its association with an octamer of 4 positively-charged core histone proteins, H2A, H2B, H3, and H4, which make up the nucleosome [21, 22] . Post-translational modifications [e.g., acetylation, phosphorylation, methylation, ubiquitylation, and small ubiquitin-related modifier (SUMO)ylation] of the histone proteins alter the DNA-nucleosome and internucleosomal interactions, thereby affecting both global and local chromatin structure [23] . Therefore, the chromatin structure is in a continuous dynamic state of repression and accessibility for particular genes, and is regulated by the pattern of histone posttranslational modifications, referred to as the histone code [24] . The activity of epigenetic factors that write/erase and read the histone code allows for the translation of cell signaling pathways into altered genomic expression profiles.
There is extensive evidence that regulation of histone post-translational modifications contribute to the etiology and progression of ischemic damage in the brain [25] [26] [27] [28] .
Acetylation
One of the most extensively studied histone modifications in general and in regard to cerebral ischemia is acetylation. Acetylation neutralizes the positive charge of lysine residues on the histone tail thereby opening local chromatin configurations, relaxing the DNA:nucleosomal association, and allowing nucleosomal repositioning thereby creating accessibility to transcription factors and associated proteins. [29] demonstrated that histone H3 acetylation levels were reduced following 6 h of MCAO. Treating the mice with the HDAC inhibitor suberoylanilide hydroxamic acid maintained histone H3 acetylation levels following MCAO and reduced the level of ischemic damage. Similar protection of histone acetylation levels and reduction in infarct volume was also observed in rats treated with the HDAC inhibitor valproic acid following 1 h MCAO [30] . In fact, numerous cerebral ischemia studies in both mice and rats have demonstrated that HDAC inhibition maintains histone acetylation levels, reduces infarct volume, and improves functional recovery following ischemia [29] [30] [31] [32] [33] [34] . Other HDAC inhibitors that have been shown to protect against neuronal ischemic damage include sodium 4-phenylbutyrate, trichostatin A and sodium butyrate [29] [30] [31] [32] [33] [34] ( Table 1 ). The studies discussed above suggest HDAC inhibitors alter the epigenetic profile of the brain from ischemic damage to survival by maintaining histone acetylation levels and by altering transcriptional activity thereby decreasing neurodegenerative protein expression while increasing prosurvival protein expression [29] [30] [31] [32] [33] [34] .
In the abovementioned studies, HDAC inhibitors were administered during or shortly after the induction of ischemia. Administration of sodium butyrate 24 h prior to and then again 4 h prior to permanent MCAO reduced infarct size by approximately 50 % at 24 h when compared with vehicle-treated controls [33] . This finding suggests that HDAC inhibition may be able to precondition the brain against ischemic damage, as has been demonstrated in the heart using the HDAC inhibitor trichostatin A [35] .
Recently, it has been demonstrated that the class III nicotinamide adenine dinucleotide (NAD + )-dependent HDAC, sirtuin 1 (SIRT1), is required for preconditioning-mediated ischemic tolerance. SIRT1 is a member of the sirtuin family of deacetylase and ADP-ribosylase enzymes, which are involved in numerous cellular activities, including the cellular stress response, genome stability, and energy metabolism [36, 37] . In contrast to ischemic neuroprotection by class I, II, and IV HDAC inhibitors (which do not inhibit sirtuins), our laboratory, and others, have demonstrated that SIRT1 activation is required for ischemic tolerance [38, 39] . Our laboratory has demonstrated both in vivo and in organotypic hippocampal slices that nuclear SIRT1 activity is increased at 48 h following IPC and that blocking SIRT1 activation with sirtinol abrogated IPC-mediated ischemic neuroprotection [38, 39] . We have also demonstrated that preconditioning could be induced, both in vivo and in hippocampal organotypic slices with the SIRT1 activator, resveratrol. Resveratrol-mediated neuroprotection was lost in the presence of sirtinol, confirming a role for SIRT1 in resveratrolmediated ischemic neuroprotection [38, 39] . Using a different model of preconditioning, Yan et al. [40] demonstrated that hyperbaric oxygen preconditioning increased SIRT1 protein [38] expression and that inhibition of SIRT1 deacetylase activity with EX527 blocked hyperbaric oxygen preconditioning neuroprotection against MCAO-mediated damage. It is interesting to note that transgenic mice overexpressing neuronalspecific SIRT1 are not protected against ischemic damage, suggesting that other signaling pathways may work in conjunction with SIRT1 for the induction of ischemic tolerance [41] . The conflicting requirements of SIRT1 activation for ischemic tolerance and HDAC (class I , II, and IV) inhibition for ischemic neuroprotection may stem, in part, from the NAD + requirement for SIRT1 enzymatic activity. The coupling of SIRT1 activity to cellular NAD + levels places SIRT1 in a position of nutrient sensing and energy metabolism by the cell. Therefore, SIRT1 alters the cellular physiology for ischemia-induced energy deprivation by increasing mitochondrial biogenesis and efficiency, increasing antioxidant protein expression, and by activation of hypoxia-inducible transcription factor pathways, to name a few (reviewed in [36] and [37] ). In the ischemia/reperfused heart, SIRT1 is activated and provides a degree of protection [42] , but not at the level observed when SIRT1 is activated prior to the injurious ischemic insult.
SIRT1 neuroprotection may stem, in part, from alteration of the epigenetic profile of the cell through the deacetylation of both histone and non-histone proteins. For example, SIRT1 is known to deacetylate histone H3 at lys9 and 14, and histone H4 at lys16 [43] . In the heart, SIRT1 decreases p300 protein levels (a histone acetyltransferase) [44] , which, combined with histone deacetylation, would result in a more repressive and transcriptionally silent chromatin structure. SIRT1 has also been demonstrated to bind to and deacetylate DNMT, thereby increasing or decreasing its methyltransferase activity depending upon the lysine residue deacetylated [45] . As discussed in the previous section, DNA methylation is a major epigenetic factor leading to gene silencing. SIRT1 has also been demonstrated to deacetylate methyl-CpG-binding protein 2 (MeCP2). Deacetylated MeCP2 is released from methylated CpG sites within the brain-derived neurotrophic factor promoter, thus leading to increased expression of brainderived neurotrophic factor, a known neuroprotective protein [46] . SIRT1 may also regulate a neuroprotective phenotype through the deacetylation and thus activation or inhibition of transcription factors, transcriptional co-activators, and nuclear receptors [37] . Based upon these studies it appears that SIRT1 may regulate the epigenetic status of the cell at various levels, including global changes in chromatin configuration, more specific modulation of histone modifications and DNA methylation at specific gene promoters, and modulating the activity of transcription factors (Fig. 2) .
These studies suggest that the epigenetic profiles of ischemic protection by HDAC inhibitors and IPC are quite different, with HDAC inhibitors maintaining acetylation levels and IPC decreasing acetylation levels via SIRT1 activation [42] .
The similarities and differences in the epigenetic profile of IPC and HDAC inhibition during ischemia are unclear, but suggest that multiple gene expression profiles exist with each leading to ischemic neuroprotection.
Methylation
Cortical spreading depression (CSD) is one of the stimuli by which ischemia tolerance can be induced in brains [47, 48] . In the rat brain, 24 h after CSD, Rana et al. [47] evaluated the effects of CSD preconditioning on histone H3 lysine 4 (H3K4) and histone H3 lysine 9 (H3K9) di-methylation level in loci affected by CSD-induced preconditioning. CSD resulted in decreased H3K4, but increased H3K9 dimethylation of 2 long interspersed sequences, suggesting alteration of epigenetic regulation of retrotransposable sequences. Selective analysis of 2 neuroprotective genes (inducible nitric oxide synthase and hypoxia-inducible factor-1α) also confirmed decreased H3K4 and increased H3K9 dimethylation. The study concluded that CSD-induced preconditioning can alter expression of neuroprotective genes and retrotransposable sequences by histone methylation-mediated epigenetic regulation.
SUMOylation
SUMO conjugation is another epigenetic factor affecting gene expression through alteration of the histone code, chromatinmodifying enzymes, promoter-specific transcription factors, and chromatin-associated proteins [49] . SUMOylation is shown to regulate HDAC recruitment to promoters, and regulation of mono-or di-methylation of H3K4 via affecting histone demethylase LSD1 [49] . It is interesting to note that SIRT1 is post-translationally SUMOylated, which increases its deacetylase activity and its anti-apoptotic activities [50] . SUMOylation plays an important role in neuroprotection in models of hibernation and ischemia tolerance. Hibernators naturally tolerate severe reductions in cerebral blood flow during torpor [51, 52] . For example, our laboratory previously observed that arctic ground squirrels (Urocitellus parryii) are remarkably tolerant to global cerebral ischemia during euthermia [53, 54] . Massive protein SUMOylation (including increased SUMO signal in cell nuclei) is reported to occur during torpor in 13-lined ground squirrels (Spermophilus tridecemlineatus) [52] . In the same study they also observed that preconditioning increased SUMO conjugation levels in SHSY5Y neuroblastoma cells. SHSY5Y neuroblastoma cells overexpressing Ubc9 (the SUMO-specific E2-conjugating enzyme) were highly resistant to OGD compared with wild-type cells. This study suggests that SUMOylation is necessary and sufficient for the induction of tolerance against OGD-induced damage [52] . In another study Lee et al. [55] observed that, following OGD preconditioning, cultured cortical neurons had elevated SUMO-1 conjugation levels compared with non-preconditioned cells. They also observed that cortical neurons and SHSY5Y cells overexpressing SUMO-1 or SUMO-2 tolerated severe OGD. Overall, these studies demonstrate that preconditioning-induced alterations in protein SUMOylation may play an important role in induction of tolerance against severe cerebral ischemia. However, downstream targets of protein SUMOylation remain to be identified in models of cerebral ischemia tolerance.
ncRNA A third mechanism of epigenetic regulation is that of ncRNA. There is increasing evidence that ncRNA, by mechanisms not yet fully defined, recruit histone-modifying enzymes and DNA methyltransferases to specific genomic loci thereby affecting epigenetic memory, chromatin architecture, and transcriptional regulation of the cell [56, 57] . Several types of ncRNA have been identified, with microRNA (miRNA) being the best described.
Numerous studies have demonstrated that miRNA expression is altered in the brain following ischemia and contributes to the etiology of ischemic injury. In a MCAO model of cerebral ischemia it was shown that miRNA expression is highly selective and temporally regulated [58] . Changes in the miRNA transcriptome were observed as early as 3 h following reperfusion and lasted for at least 72 h. Ischemia/reperfusion-induced changes in miRNA expression profiles correlated with altered expression of the predicted miRNA target proteins, many of which are involved in transcriptional regulation, inflammation, ionic flux, neuroprotection, and receptor function [58] . These cellular functions are associated with the ischemia/reperfusion pathological response, suggesting altered miRNA expression may contribute significantly to the ischemia/reperfusion damage.
Although ischemia has been demonstrated to alter the expression profile of numerous miRNAs, only a few of these have been experimentally demonstrated to functionally contribute to ischemic cell damage. For example, miR-15a expression is increased in vascular endothelial cells following acute OGD, and was demonstrated to inhibit expression of Conversely, SIRT1 can increase gene expression through deacetylating lysine residues within a lysine-glycine repeat region in DNMT1 thereby reducing DNMT1 activity leading to DNA hypomethylation, and through the deacetylation-dependent activation of transcription factors (TF) and inactivation of transcriptional repressors such as methyl-CpG binding protein 2 (MeCP2) the anti-apoptotic gene B-cell lymphoma 2 (bcl-2) leading to cell death. Inhibition of miRNA-15a expression in vivo increased bcl-2 protein levels, and reduced cerebral infarct volume in mice following 60 min of MCAO [59] . Similarly, miR-497 expression was increased following transient MCAO and was demonstrated to inhibit bcl-2 and bcl-w expression. Knockdown of miR-497 in mice prevented the downregulation of bcl-2 and bcl-w protein levels in the infarcted region, and attenuated infarct volume and improved neurologic outcome following ischemia [60] .
miRNAs have also been demonstrated to be involved in the epigenetic reprogramming of the brain in ischemic tolerance. Several studies have demonstrated that IPC alters the miRNA transcriptome. For example, Dharap and Vemuganti [61] found that 26 miRNAs were upregulated and 25 miRNAs downregulated in the rat cerebral cortex following IPC, with 20 of these miRNAs maintaining altered expression for 3 days. In the mouse cortex, Lusardi et al. [62] compared miRNA expression from preconditioned and injurious ischemic groups, and found that miRNA expression is preferentially upregulated by IPC, but predominately downregulated by injurious ischemia. Bioinformatic analysis of miRNA expression revealed that IPC differentially regulates miRNAs that primarily target transcriptional regulators. For example, one of the most notable downregulated miRNAs was miR-132, which regulates MeCP2 expression, a major regulator of gene expression. Consistent with the miRNA findings, MeCP2 protein expression was increased in the IPC brain and was required for ischemic tolerance, as knocking out MeCP2 expression in mice abrogated IPCmediated neuroprotection [62] .
Conclusions
Ischemic tolerance represents the end product of numerous signaling pathways, which transiently act in concert to modify the activity of epigenetic proteins, which, in turn, collectively alter the genomic expression profile of the cell, leading to neuroprotection. Therefore, the activation or inhibition of gene sets versus individual signaling pathways may represent a viable approach for the therapeutic intervention for cerebral ischemia. However, we are clearly only in the infancy of our understanding of the multitude of epigenetics mechanisms mediating ischemic tolerance or injury. The participation of DNA, histone, and non-histone chromatinassociated proteins, as well as ncRNAs, underscores a level of complexity of the epigenetic response of the cell to ischemic stress that will take an important effort to understand. The continued failure of clinical trials for stroke beckons for alternative approaches for ischemic neuroprotection which may be based on this newly acquired knowledge of epigenetics. As discussed in this review, the data collected thus far demonstrate that further investigations into the epigenetics of ischemic cell death and IPC-mediated ischemic neuroprotection are well justified and may well lead to novel targets for ischemic neuroprotection.
